1. Applying the 2007 asthma guidelines: the Asthma APGAR Barbara P. Yawn, MD MSc FAAFP Member EPR-3 panel Director of Research Olmsted Medical Center Rochester, MN Adjunct Professor, Family and Community Health University of Minnesota byawn@olmmed.org

2. Objectives: Use cases as examples Apply the guidelines Discuss areas of judgment and evidence Highlight use of severity and control Highlight hierarchy of pharmacotherapy Highlight importance of non-pharma-- cotherapy

3. Care should focus on: Outcomes that matter to patients Outcomes that matter to families Outcomes that matter to clinicians Outcomes that matter to quality monitors In that order

4. Work Absenteeism Presenteeism Promotion

5. Play Focus on Fun Person centered Not disease centered

6. Sleep Enough Not interrupted

7. $,$,$ Not consumed by asthma

8. Outcomes that matter to families

9. More normal lifestyle Simple treatment plans –?? Long acting medications –Lowest amount of therapy—step down Fewer urgent visits –Schedule regular visits –Know what to do during those visits Have a plan for regular visits

10. More “normal” lifestyle (con’t) No hospitalizations –Prevention –Chronic care attitude Less stress and less obsession with asthma –Knowing what to do to help –Knowing how to assess level of control Education, tools for self assessment

11. Practice outcomes Fewer unscheduled visits Fewer phone calls Shorter phone calls Better self management Written plans or any plans

12. Meeting Quotas or Outcomes That Matter to Administrators Correct drug ratios “Appropriate” use of medications Fewer ED and urgent care visits Fewer hospitalizations HEDIS Pay for performance Others??

13. First priority is to meet patient and family needs Understand disease from their perspective Affirm their concerns Negotiate a common ground and goals Provide environment for communication and education Control symptoms Patient Centered Focus

14. Make sure it is asthma Correct diagnosis and uniform terminology RAD, chronic bronchitis, wheezy bronchitis wheezy bronchitis Symptoms PFT Allergies

15. Your diagnosis? Danny comes for catch up immunizations 2 months ago hospitalized for RSV—negative RSV Coughing and wheezing responded to beta agonists and inhaled steroids given by nebulizer. Discharged on ICS and SABA by inhaler and mask. Medications continued for about 6 weeks and DC’d. Danny’s mother asks about the ‘reactive airway disease’ she overheard the hospital nurses report as Danny’s diagnosis.

16. Danny’s respiratory history Recurrent bouts of airflow limitations Atopy by history Family history of asthma Improved with beta agonists Stayed better with steroids

17. Differential Diagnosis: Upper airway –AR and AR Sinusitis Large airway –FB, VCD, Vascular rings, tracheomalacia Small airways –Viral, CF, BPD, heart disease Other –GE reflux

18. No objective measures so: Initial diagnosis Rx Reassess Initial diagnosis Rx Reassess 50% to 80% of children who develop asthma will have asthma symptoms before age 5

19. Danny Danny is not a candidate for spirometry testing Diagnosis based on pattern of symptoms, risk factors and response to therapy. He has had 2 hospitalizations for “pneumonia” Two negative chest x-rays Therefore, cardio-vascular disease, and foreign body aspirations are unlikely. Of differential diagnoses, asthma is most likely.

20. Danny Recurrent episodes respond to bronchodilators Has not yet been tired on inhaled ICS therapy. Called “reactive airway disease”(RAD) It may be used temporarily Using the diagnosis of RAD does not reassure patients nor improve a child’s care. In fact it may confuse and anger patients.[21]) We are ready to talk to Danny’s parents about asthma and to begin asthma therapy.

21. Classifying severity PUT ASTHMA APGAR HERE! Symptoms at least three or four days a week Wakes up coughing at least two nights a week Mother watches his fatigue level before going to play dates or YMCA Not taking any medication currently

22. Components of Severity Classification of Asthma Severity (Children 0  4 years of age) Intermittent Persistent MildModerateSevere Impairment Symptoms  2 days/week >2 days/week but not daily Daily Throughout the day Nighttime awakenings 0 1  2x/month 3  4x/month >1x/week Short-acting beta 2 -agonist use for symptom control (not prevention of EIB)  2 days/week >2 days/week but not daily Daily Several times per day Interference with normal activity None Minor limitation Some limitation Extremely limited Risk Exacerbations (consider frequency and severity) 0  1/year  2 exacerbations in 6 months requiring oral steroids, or  4 wheezing episodes/1 year lasting >1 day AND risk factors for persistent asthma Frequency and severity may fluctuate over time Exacerbations of any severity may occur in patients in any severity category

23. Intermittent Asthma Persistent Asthma: Daily Medication Consult with asthma specialist if step 3 care or higher is required. Consider consultation at step 2. Quick-Relief Medication for All Patients SABA as needed for symptoms. Intensity of treatment depends on severity of symptoms. With viral respiratory infection: SABA q 4 – 6 hours up to 24 hours (longer with physician consult). Consider short course of systemic oral corticosteroids if exacerbation is severe or patient has history of previous severe exacerbations. Caution: Frequent use of SABA may indicate the need to step up treatment. See text for recommendations on initiating daily long-term-control therapy. Step 1 Preferred: SABA PRN Step 2 Preferred: Low-dose ICS Alternative: Montelukast or Cromolyn Step 3 Preferred: Medium-dose ICS Step 5 Preferred: High-dose ICS AND Either: Montelukast or LABA Step 6 Preferred: High-dose ICS AND Either: Montelukast or LABA AND Oral corticosteroids Choose step to correspond to level of severity and history of exacerbations Patient Education and Environmental Control at Each Step Step 4 Preferred: Medium-dose ICS AND Either: Montelukast or LABA Assess control

24. Approved drugs for Danny ICS budesonide nebulizer solution (1–8 years of age) ICS fluticasone DPI (4 years of age and older) Long-acting inhaled beta2-agonist (LABA) salmeterol DPI and combination product (salmeterol + fluticasone) DPI (4 years of age and older) LTRA montelukast, based on safety data rather than efficacy data, in a 4 mg chewable tablet (2– 6 years of age) and in 4 mg granules (1 year of age) Cromolyn nebulizer (2 years of age and older)

25. Therapy choices for Danny Persistent asthma Mild to moderate Candidate for anti-inflammatory therapy First choice is inhaled ICS –Low dose

26. How will ICS be administered? <3 years--nebulizer therapy for budesonide and cromolyn. 3 to 5 years may begin with an MDI and spacer or VHC alone Face mask plus –Valved chamber (VHC) –Nebulizer –Masks must fit properly and properly held on face Caregivers must be instructed –proper use of nebulizers and VHC, –appropriate size and use of face masks “Blow by” technique is not appropriate.

27. Planned care Begin Danny on ICS low dose Nebulizer and face mask See back in two weeks, reassess APGAR Begin education about asthma related to mother’s desire for “what information first”

28. Now Mary using control status Mary is 10, comes for recheck Asthma diagnosed 2 yrs ago. Recorded as mild persistent asthma Prescribed daily low dose ICS 3 refills over past 6 months Increasing problems with wheezing during school Been to school health aid almost daily for 3 weeks.

29. Asthma Severity

30. Mary continued: Gets a dose of her “rescue” medication, improves rapidly and back to class in about 30 min. No action plan. Seems to always happen in math class. Mary says she is using daily ICS in the late afternoon, her mother agrees and both say her open mouth inhaler technique is good. No problems on weekends or after school.

31. Assessing symptoms: Don’t ask --- Don’t tell --- Don’t Document Has never worked for anything!!!!!

32. How Can We Assess Control? 1,2 Activity limitations? Daytime symptoms? Missed work and/or school? Nighttime awakenings? Lung function? Asthma Control Use of quick- reliever? Utilization of healthcare resources? Patient self-report of control? Direct or indirect inflammation? Satisfaction with care? 1.Luskin AT. Slides presented at: Annual Meeting of ACAAI; 2006; Philadelphia, Pa. 2.Global Initiative for Asthma (GINA). Revised 2006. Available at: www.ginasthma.org.

33. Need more data to do control assessment Risk and impairment Symptoms Missed or modified activities Use of SABAs Objective lung function measures Current medications

34. Objective lung function testing: Diagnosis of asthma requires: –Evidence of reversible airway obstruction 12% increase in FEV, after beta agonist Children <5 – presumptive based on decreased symptoms after beta agonist Improved peak flow can be used if spirometry not available Mary has not had spirometry

35. The flow-volume curve FVC The F-V curve was invented to make the recognition of spirometry patterns easier. The exhalation starts here You can’t measure the FEV1 from F-V curves. peak flow

36. Components of Control Classification of Asthma Control (5  11 years of age) Well Controlled Not Well Controlled Very Poorly Controlled Impairment Symptoms  2 days/week but not more than once on each day  2 days/week but not more than once on each day >2 days/week or multiple times on  2 days/week >2 days/week or multiple times on  2 days/week Throughout the day Throughout the day Nighttime awakenings  1x/month  2x/month  2x/week Interference with normal activity None Some limitation Extremely limited Short-acting beta 2 -agonist use for symptom control (not prevention of EIB)  2 days/week >2 days/week Several times per day Lung function FEV 1 or peak flow FEV 1 or peak flow >80% predicted/ personal best 60  80% predicted/ personal best <60% predicted/ personal best FEV 1 /FVC FEV 1 /FVC >80% predicted 75  80% predicted <75% predicted Risk Exacerbations 0  1 per year 2  3 per year >3 per year Reduction in lung growth Evaluation requires long-term followup. Treatment-related adverse effects Medication side effects can vary in intensity from none to very troublesome and worrisome. The level of intensity does not correlate to specific levels of control but should be considered in the overall assessment of risk.

37. Various Factors Contributing to the Variability of Asthma Host Genetic predisposition AtopyHyperresponsiveness Activity level Perception Medication adherence Environment Occupational sensitizers Tobacco smoke Air pollutants Respiratory infections Socioeconomic factors Allergen exposure Global Initiative for Asthma NIH/NHLBI. Revised 2002. Publication no. 02-3659.

38. Asthma Control Test ™ (ACT) Nathan RA, et al. J Allergy Clin Immunol. 2004;113:59-65 1. In the past 4 weeks, how much of the time did your asthma keep you from getting as much done at work, school or at home? All of the time 1 Most of the time 2 Some of the time 3 A little of the time 4 None of the time 5 2. During the past 4 weeks, how often have you had shortness of breath? >1x/day11x/day23-6x/wk31-2x/wk4 Not at all 5 3. During the past 4 weeks, how often did your asthma symptoms (wheezing, coughing, shortness of breath, chest tightness or pain) wake you up at night or earlier than usual in the morning?  4 nights/wk 1 2-3 nights/wk 21x/wk3 Once or twice 4 Not at all 5 4. During the past 4 weeks, how often have you used your rescue inhaler or nebulizer medication (such as albuterol)?  3 times/day 1 1-2 x/day 22-3x/wk3 1x/wk or less 4 Not at all 5 5. How would you rate your asthma control during the past 4 weeks? Not controlled at all 1 Poorly controlled 2 Somewhat controlled 3 Well controlled 4 Completely controlled 5

39. Asthma APGAR

40. Intermittent Asthma Persistent Asthma: Daily Medication Consult with asthma specialist if step 4 care or higher is required. Consider consultation at step 3. Step 1 Preferred: SABA PRN Step 2 Preferred: Low-dose ICS Alternative: LTRA Cromolyn, Nedocromil, or Theophylline Step 3 Preferred: Medium-dose ICS OR Low-dose ICS + either LABA, LTRA, or Theophylline Step 5 Preferred: High-dose ICS + LABA Alternative: High-dose ICS + either LTRA or Theophylline AND Omalizumab may be considered for patients who have allergies Step 6 Preferred: High-dose ICS + LABA + oral corticosteroid Alternative: High-dose ICS + either LTRA or Theophylline + oral corticosteroid AND Omalizumab may be considered for patients who have allergies Step up if needed (first, check adherence and environmental control and comorbid conditions) Step down if possible (and asthma is well controlled at least 3 months) Patient Education and Environmental Control at Each Step Step 4 Preferred: Medium-dose ICS + LABA Alternative: Medium-dose ICS + either LTRA or Theophylline Assess control Quick-Relief Medication for All Patients SABA as needed for symptoms. Intensity of treatment depends on severity of symptoms: up to 3 treatments at 20-minute intervals as needed. Short course of systemic oral corticosteroids may be needed. Caution: Increasing use of beta-agonist or use >2 times a week for symptom control (not prevention of EIB) indicates inadequate control and the need to step up treatment.

41. APGAR Algorithm

42. But for Mary we need more Why such an unusual pattern? Problem with math class –Likes math and does well –Doing well even missing class –Doesn’t like missing math What happens just before math class –Recess –Playing out doors

43. Triggers and Allergens Exercise?Pollens? Other envirnomental things?

44. Where to look for help Websites for current outdoor allergen levels include: http://www.usatoday.com/life/health/allergies/seas onal.htm http://www.usatoday.com/life/health/allergies/seas onal.htm http://www.weather.com/activities/health/pollen/http://www.weather.com/activities/health/pollen/. http://www.weather.com/activities/health/pollen/ Allergic rhinitis common Allergic rhinitis symptoms can be very helpful in determining the presence of seasonal versus persistent exposure to allergens of consequence

45. Mary Consider increasing therapy for pollen season Consider using pre-med before recess Consider keeping Mary in from recess Must reassess after first freeze

46. KISS IT Choose the essential elements Focus on a few Let them ask for more Translate to the basic tasks of any clinical visit Make it flexible Use their data

47. ASTHMA APGAR A=ActivitiesP=PersistenceG=triGGers A=Asthma Medications R=Response to Therapy

48. Phase 1 Apgar 4 Sites: Rural Family Practice 1 st Meeting: Asthma CME & Apgar –MD & RN abstract 10-20 charts 2 nd Meeting: Review Data –Gaps Identified by Staff –Ideas for Practice Change Utilize Apgar in practice 3 months Review Additional 10 charts

49. Phase 1: 1st Abstraction

50. Gaps Identified Knowing what to ask in asthma evaluation. Know how to do asthma evaluation and record it. Don’t know what medications patient really taking. Inhalers not identified by patients as medication Staff and patients need review of inhaler technique Do not know asthma symptom frequency and activity limitations based on documentation. Patient history not clear to physicians. Difficult to follow progression of care. Do not know when asthma patient is being seen in clinic for other reasons.

51. Practice Changes Breathing evaluation for patients Memory aids for staff Pink Lung Apgar Wallet sized Apgar Red stamp on visit sheet identifies those with asthma/smokers Electronic template Inhaler technique information sheets Language change when asking patients to bring in medications Staff review inhaler technique once/yr Have patients demonstrate inhaler technique

52. Phase 1: 2 nd Data Abstraction

53. Phase 1: % CHANGE Pre vs. Post data set

54. ISSUES ISSUES Documentation Patients minimize their disease. Asthma not viewed as chronic illness. ActivitiesTriggersMedications Allergy testing. Response to Therapy Nurses/Asthma educators Patient should be the one to determine how he/she is doing. Time is an issue Streamline

55. Phase 2 asthma Apgar 10 Minnesota FP Sites agree to participate Contact only by phone –Teach abstract process using Apgar Reviewed 20 charts Telephone Conference to review data –Identify Gaps in care –Identify Practice Changes –Implement practice changes x3 months Review additional 20 charts Review additional 20 charts

56. Phase 2 Comments “I’m sure we’re doing OK, but you can’t prove it by reading the note (in the chart).” “We ask more than we chart.” “We’re making a lot of work for each other due to a lack of charting.” “This (Apgar) was a cognitive leap; it’s not something I think about. I need to add it to my assessment with adults.” Data represents increase in practitioners’ time if charting is not done adequately. Inadequate charting is represented by other diseases as well, i.e. diabetes, heart disease.

57. Moving to Patient Apgar Participatory research Start with previous work Conceptualize the tool Plan implementation strategies Develop outcome measures Develop methods to collect outcome measures

58. General principle #1 The physician’s and nurses’ question determine the tone and specificity of the visit. How is your asthma doing? I would like to know about how asthma is affecting you. –APGAR questions

59. General principle #2 What we ask is what the patients will perceive we think is important They will begin to notice what we ask them to evaluate

60. General principle #3 APGAR concept work for all chronic diseases –How does disease impact your activities? –How often are you having symptoms? DayNight –What makes it better and worse –How are you actually able to take medications –Do the medications make it better or worse

61. One plan for most conditions Asthma Apgar as a template Processes that can be translated Practice friendly processes Patient friendly processes

62. Asthma Management Plan

64. Asthma Management Severity assessed by Asthma APGAR Asthma APGAR at each visit for “ control+” Modifications (not just drugs) Why inadequate? Inadequate Adequate Adherence Triggers Co-morbidities Psycho-social Inhaler technique Risk Select therapy